RxDoctor Payments DataLook up a doctor →

Thomas Jones, MD

Endocrinology, Diabetes & Metabolism · Macon, GANPI 1740208966

Payments from drug & device makers

$4,838,128in general payments, 2019–2025

Across 986 payments — averaging $4906.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3.9M
  • AbbVie$407K
  • Sanofi US Services Inc.$258K
  • Insulet Corporation$212K
  • Medtronic$39K
  • Tandem Diabetes Care, Inc.$23K
  • plus $19K from 49 others
$73,094in research payments, 2019–2025

Across 11 payments — averaging $6644.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$73K

What the payments were for

  • Speaking & faculty fees$24,15064%
  • Travel & lodging$7162%
  • Food & beverage$12,51133%
  • Education$2651%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,838,128 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia

Medicare billing

Part B allowed, 2024
$75,566
Medicare patients
327
Services billed
3,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide348$564,428
JardianceEmpagliflozin183$208,981
Tresiba Flextouch U-200Insulin Degludec112$127,784
MounjaroTirzepatide67$84,262
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/749$69,254
TrulicityDulaglutide49$61,187
Tresiba Flextouch U-100Insulin Degludec87$55,179
ForteoTeriparatide12$50,046
JanuviaSitagliptin Phosphate51$46,531
FarxigaDapagliflozin Propanediol43$42,988
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt17$31,158
Soliqua 100-33Insulin Glargine/Lixisenatide13$30,115
RybelsusSemaglutide28$28,463
Fiasp FlextouchInsulin Aspart (Niacinamide)29$28,160
SynthroidLevothyroxine Sodium264$23,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,809$612,320423 claims
Lilly USA, LLCMounjaro, Trulicity, Forteo, Lyumjev, Humalog$1,507$225,875207 claims
Boehringer IngelheimJardiance, Synjardy$722$212,852196 claims
MerckJanuvia$104$46,53151 claims
AstraZenecaFarxiga$292$42,98843 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$701$32,07534 claims
AbbVieSynthroid$406,725$23,786264 claims
Johnson & JohnsonInvokana$311$19,00722 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$398$3,549320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

Other endocrinology, diabetes & metabolism in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →